Selumetinib has been tested in clinical trials for MPNST treatment, primarily focusing on developing effective combination strategies with the mTOR inhibitor sirolimus (NCT03433183) or the bromodomain inhibitor AZD5153 plus the programmed death-ligand 1 (PD-L1) antibody durvalumab (NCT05253131) [45]. Here, MTOR is linked to malignant peripheral nerve sheath tumor.